-Reuters
Raymond James Maintains Outperform on MeridianLink, Lowers Price Target to $20
Raymond James analyst Brian Peterson maintains MeridianLink (NYSE:MLNK) with a Outperform and lowers the price target from $21 to $20.
Related Posts
Outset Medical Q2 EPS $(0.92) Down From $(0.66) YoY, Sales $25.06M Down From $25.22M YoY
Outset Medical (NASDAQ:OM) reported quarterly losses of $(0.92) per share. This is a 39.39 percent decrease over losses of $(0.66) per share from the same period last year. The company reported $25.06 million in sales
VYNE Therapeutics Shares Disappointing Data From Atopic Dermatitis Trial
VYNE Therapeutics Inc (NASDAQ: VYNE) has announced results from the Phase 2a segment of Phase 1b/2a trial evaluating FMX114 for mild-to-moderate atopic dermatitis.
Recap: NortonLifeLock Q1 Earnings
NortonLifeLock (NASDAQ:NLOK) reported its Q1 earnings results on Thursday, August 4, 2022 at 04:15 PM.
Here's what investors need to know about the announcement.
Earnings
NortonLifeLock beat estimated earnings by 4.65%, reporting an EPS of $0.45 versus an estimate of $0.43.